AADI

Aadi Bioscience, Inc. [AADI] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

AADI Stock Summary

Top 10 Correlated ETFs

AADI

Top 10 Correlated Stocks

AADI

In the News

AADI Financial details

Company Rating
-
Market Cap
48.13M
Income
-64.22M
Revenue
24.35M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
89
Optionable
No
Shortable
Yes
Earnings
08 May 2024
P/E
-0.77
Forward P/E
-
PEG
1.3
P/S
1.87
P/B
0.4
P/C
-
P/FCF
-0.67
Quick Ratio
6.1
Current Ratio
6.48
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.38
EPS next Y
-
EPS next Q
-
EPS this Y
-3.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-22.27%
Revenue last 5Y
100.64%
Revenue Q/Q
6.16%
EPS Q/Q
-
-
-
-
-
SMA20
-17.91%
SMA50
-43.69%
SMA100
-22.9%
Inst Own
-
Inst Trans
-
ROA
-44%
ROE
-45%
ROC
-0.58%
Gross Margin
91%
Oper. Margin
-300%
Profit Margin
-266%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.55-8.65
52W High
-78.63%
52W Low
+71%
RSI
37.54
Rel Volume
0.07
Avg Volume
374.81K
Volume
25.41K
Perf Week
4.27%
Perf Month
-25.65%
Perf Quarter
-
Perf Half Y
-18.57%
-
-
-
-
Beta
0.298
-
-
Volatility
0.04%, 0.19%
Prev Close
4.27%
Price
1.71
Change
1.18%

Something similar

Top by Market Cap
NVDA
TL0.DE
AMZ.DE
VOO
BRYN.DE
Top Correlated ETFs
GXTG
EDOC
DXW.TO
SHPP
ZZZD.TO
Top Correlated Stocks
0KT6.L
8245.HK
LKCO
1803.HK
0834.HK
Similar Market Cap
MBTCU
PALT
LONG.TO
WTEL.L
NTRB

Company Profile

Healthcare Biotechnology
  • Volume Average 374.81K
  • Market Capitalization 48.13M
  • Employee 89
  • CEO Mr. David J. Lennon Ph.D.
  • Headquarters Pacific Palisades,CA,US
  • IPO Date 2018-02-16
  • Website https://aadibio.com

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.